Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Research in Innate and Adaptive Immunity
share announcement

Research in Innate and Adaptive Immunity

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Innate and Adaptive Immunity in Vaccination".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 5648

Special Issue Editors

Dr. Jose Moisés Laparra

E-Mail Website
Guest Editor
Molecular Immunonutrition Group, Madrid Institute for Advanced Studies in Food (IMDEA-Food), 28049 Madrid, Spain
Interests: immunonutrition; macrophages; trained immunity; gut-liver axis; microbiota
Special Issues, Collections and Topics in MDPI journals
Dr. Juan Antonio Giménez-Bastida

E-Mail Website
Guest Editor
Laboratory of Food and Helath, Research Group on Quality, Safety and Bioactivity of Plant Foods, Department Food Science and Technology, CEBAS-CSIC, P.O. Box 164, Campus de Espinardo, 30100 Murcia, Spain
Interests: polyphenols; in vitro; in vivo; pharmacology; eicosanoids; inflammation; cardiovascular; health; bioactive molecules
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The intricate immune signals between both innate and adaptive branches of the immune system not only represent our first line of defense but also allow us to normally develop during ontogeny. These interactions take place sequentially to establish adequate metabolic and microbial commensal response(s), offering protection to exogenous biological entities and to an exaggerated inflammation. Complex cellular and humoral networks of adaptive immune cells and metabolic products are well known. However, fundamental questions remain unanswered about the interconnexion between innate and adaptive immune response(s) to immunoevasion. These will improve our knowledge on immunometabolic diseases, cancer, virus clearance, and recovery of immunocompetence. Identification and development of those with a concerted perspective will overcome the usually fragmented and compartmentalized approach to addressing the underlying immune alterations. Integrating both components in the context of its relationship to exposures (i.e., diet, environment, microbiota) and the host’s intrinsic and modifiable factors and disease outcomes will contribute toward vaccine and immunotherapeutic design and evaluation. 

Dr. Jose Moisés Laparra
Dr. Juan Antonio Giménez-Bastida
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • innate immunity
  • adaptive immunity
  • trained immunity
  • cancer
  • virus
  • neuroimmunology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

25 pages, 4063 KiB  
Article
First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster
by Meral Esen, Johanna Fischer-Herr, Julian Justin Gabor, Johanna Marika Gaile, Wim Alexander Fleischmann, Geerten Willem Smeenk, Roberta Allgayer de Moraes, Sabine Bélard, Carlos Lamsfus Calle, Tamirat Gebru Woldearegai, Diane Egger-Adam, Verena Haug, Carina Metz, Alena Reguzova, Markus W. Löffler, Baiba Balode, Lars C. Matthies, Michael Ramharter, Ralf Amann and Peter G. Kremsner
Vaccines 2024, 12(11), 1288; https://doi.org/10.3390/vaccines12111288 - 18 Nov 2024
Viewed by 526
Abstract
The emergence of SARS-CoV-2 has necessitated the development of versatile vaccines capable of addressing evolving variants. Prime-2-CoV_Beta, a novel Orf virus-based COVID-19 vaccine, was developed to express the SARS-CoV-2 spike and nucleocapsid antigens. This first-in-human, phase I, dose-finding clinical trial was conducted to [...] Read more.
The emergence of SARS-CoV-2 has necessitated the development of versatile vaccines capable of addressing evolving variants. Prime-2-CoV_Beta, a novel Orf virus-based COVID-19 vaccine, was developed to express the SARS-CoV-2 spike and nucleocapsid antigens. This first-in-human, phase I, dose-finding clinical trial was conducted to assess the safety, reactogenicity, and immunogenicity of Prime-2-CoV_Beta as a booster in healthy adults. From June 2022 to June 2023, 60 participants in Germany received varying doses of Prime-2-CoV_Beta. The study demonstrated a favorable safety profile, with no serious adverse events (AEs) reported. All AEs were mild (107) or moderate (10), with the most common symptoms being pain at the injection site, fatigue, and headache. Immunogenicity assessments revealed robust vaccine-induced antigen-specific immune responses. High doses notably elicited significant increases in antibodies against the spike and nucleocapsid proteins as well as neutralizing antibodies against SARS-CoV-2 and its variants. Additionally, the vaccine did not induce ORFV-neutralizing antibodies, indicating the potential for repeated administration. In conclusion, Prime-2-CoV_Beta was safe, well tolerated, and immunogenic, demonstrating potential as a broadly protective vaccine against SARS-CoV-2 and its variants. These promising results support further evaluation of higher doses and additional studies to confirm efficacy and long-term protection. This trial was registered at ClinicalTrials, NCT05389319. Full article
(This article belongs to the Special Issue Research in Innate and Adaptive Immunity)
►▼ Show Figures

Figure 1

18 pages, 5087 KiB  
Article
DNA Vaccines Encoding HTNV GP-Derived Th Epitopes Benefited from a LAMP-Targeting Strategy and Established Cellular Immunoprotection
by Dongbo Jiang, Junqi Zhang, Wenyang Shen, Yubo Sun, Zhenjie Wang, Jiawei Wang, Jinpeng Zhang, Guanwen Zhang, Gefei Zhang, Yueyue Wang, Sirui Cai, Jiaxing Zhang, Yongkai Wang, Ruibo Liu, Tianyuan Bai, Yuanjie Sun, Shuya Yang, Zilu Ma, Zhikui Li, Jijin Li, Chenjin Ma, Linfeng Cheng, Baozeng Sun and Kun Yangadd Show full author list remove Hide full author list
Vaccines 2024, 12(8), 928; https://doi.org/10.3390/vaccines12080928 - 19 Aug 2024
Viewed by 968
Abstract
Vaccines has long been the focus of antiviral immunotherapy research. Viral epitopes are thought to be useful biomarkers for immunotherapy (both antibody-based and cellular). In this study, we designed a novel vaccine molecule, the Hantaan virus (HTNV) glycoprotein (GP) tandem Th epitope molecule [...] Read more.
Vaccines has long been the focus of antiviral immunotherapy research. Viral epitopes are thought to be useful biomarkers for immunotherapy (both antibody-based and cellular). In this study, we designed a novel vaccine molecule, the Hantaan virus (HTNV) glycoprotein (GP) tandem Th epitope molecule (named the Gnc molecule), in silico. Subsequently, computer analysis was used to conduct a comprehensive and in-depth study of the various properties of the molecule and its effects as a vaccine molecule in the body. The Gnc molecule was designed for DNA vaccines and optimized with a lysosomal-targeting membrane protein (LAMP) strategy. The effects of GP-derived Th epitopes and multiepitope vaccines were initially verified in animals. Our research has resulted in the design of two vaccines based on effective antiviral immune targets. The effectiveness of molecular therapies has also been preliminarily demonstrated in silico and in laboratory animals, which lays a foundation for the application of a vaccines strategy in the field of antivirals. Full article
(This article belongs to the Special Issue Research in Innate and Adaptive Immunity)
►▼ Show Figures

Figure 1

Other

Jump to: Research

21 pages, 5285 KiB  
Systematic Review
The Role of Neutrophil-to-Lymphocyte Ratio in Risk Stratification and Prognostication of COVID-19: A Systematic Review and Meta-Analysis
by Ashwaghosha Parthasarathi, Sunag Padukudru, Sumalata Arunachal, Chetak Kadabasal Basavaraj, Mamidipudi Thirumala Krishna, Koustav Ganguly, Swapna Upadhyay and Mahesh Padukudru Anand
Vaccines 2022, 10(8), 1233; https://doi.org/10.3390/vaccines10081233 - 1 Aug 2022
Cited by 27 | Viewed by 3292
Abstract
Several studies have proposed that the neutrophil–lymphocyte ratio (NLR) is one of the various biomarkers that can be useful in assessing COVID-19 disease-related outcomes. Our systematic review analyzes the relationship between on-admission NLR values and COVID-19 severity and mortality. Six different severity criteria [...] Read more.
Several studies have proposed that the neutrophil–lymphocyte ratio (NLR) is one of the various biomarkers that can be useful in assessing COVID-19 disease-related outcomes. Our systematic review analyzes the relationship between on-admission NLR values and COVID-19 severity and mortality. Six different severity criteria were used. A search of the literature in various databases was conducted from 1 January 2020 to 1 May 2021. We calculated the pooled standardized mean difference (SMD) for the collected NLR values. A meta-regression analysis was performed, looking at the length of hospitalization and other probable confounders, such as age, gender, and comorbidities. A total of sixty-four studies were considered, which included a total of 15,683 patients. The meta-analysis showed an SMD of 3.12 (95% CI: 2.64–3.59) in NLR values between severe and non-severe patients. A difference of 3.93 (95% CI: 2.35–5.50) was found between survivors and non-survivors of the disease. Upon summary receiver operating characteristics analysis, NLR showed 80.2% (95% CI: 74.0–85.2%) sensitivity and 75.8% (95% CI: 71.3–79.9%) specificity for the prediction of severity and 78.8% (95% CI: 73.5–83.2%) sensitivity and 73.0% (95% CI: 68.4–77.1%) specificity for mortality, and was not influenced by age, gender, or co-morbid conditions. Conclusion: On admission, NLR predicts both severity and mortality in COVID-19 patients, and an NLR > 6.5 is associated with significantly greater the odds of mortality. Full article
(This article belongs to the Special Issue Research in Innate and Adaptive Immunity)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop